1. Vicriviroc malate is a novel kinase inhibitor developed for cell signaling and oncology research that acts as a CCR5 receptor antagonist.
2. Studies showed that vicriviroc potently inhibited chemokine-induced migration, calcium release, and GTPS exchange in CCR5-expressing cells with IC50 values below 4.2 nM, demonstrating its ability to block CCR5 receptor signaling.
3. Selleck Chemicals produces vicriviroc malate and provides information on its product details, storage conditions, references, and ordering procedures.